Last reviewed · How we verify

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine

National Cancer Center, Korea · Phase 3 active Small molecule

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is a Combination chemotherapy regimen Small molecule drug developed by National Cancer Center, Korea. It is currently in Phase 3 development for Breast cancer (likely indication based on typical use of this combination). Also known as: Taxotere, Xeloda, Cytoxan, doxorubicin.

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms.

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms. Used for Breast cancer (likely indication based on typical use of this combination).

At a glance

Generic nameAnthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Also known asTaxotere, Xeloda, Cytoxan, doxorubicin
SponsorNational Cancer Center, Korea
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Anthracyclines intercalate into DNA and generate reactive oxygen species to kill rapidly dividing cells. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Docetaxel stabilizes microtubules to prevent mitotic spindle formation. Capecitabine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA. Together, these agents provide synergistic cytotoxic effects against cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine

What is Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is a Combination chemotherapy regimen drug developed by National Cancer Center, Korea, indicated for Breast cancer (likely indication based on typical use of this combination).

How does Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine work?

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms.

What is Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine used for?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is indicated for Breast cancer (likely indication based on typical use of this combination).

Who makes Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is developed by National Cancer Center, Korea (see full National Cancer Center, Korea pipeline at /company/national-cancer-center-korea).

Is Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine also known as anything else?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is also known as Taxotere, Xeloda, Cytoxan, doxorubicin.

What drug class is Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine in?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine in?

Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine is in Phase 3.

What are the side effects of Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine?

Common side effects of Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Mucositis, Cardiotoxicity (anthracycline-related).

Related